EZH2 and acute myeloid leukemia: From a clinical standpoint, inactivation of EZH2 by loss or mutation in MDS is enlightening as cytogenetic abnormalities of chromosome 7 which have been long recognized in MDS and AML and linked to adverse outcome [73, 74].